Omnes Capital's exits

Sector 
SaaS / Cloud
Entry Date 
2005
Exit Date 
2011
Buyer 
Keynetis
Business 
Venture Capital

OpenTrust

From defensive security to digital trust

OpenTrust (formerly Idealx) develops software solutions to move on from defensive security to digital trust based on a “Trusted Ecosystem” in which each component (routers, networks, machines, servers, users, systems, applications, transactions, etc.) must trust the calling component and/or the one being called before it is executed. OpenTrust has more than one million users around the world who work for 70 large accounts and public administrations.

Sector 
Pharma
Entry Date 
2003
Exit Date 
2011
Buyer 
Amgen
Business 
Venture Capital

Biovex

Oncolytic vaccines used to treat cancer and infectious diseases

Biovex, which was founded in 1998, develops new vaccines used to treat cancer and chronic infectious diseases. The company has two proprietary platforms, namely OncoVEX and ImmunoVEX, based on genetic manipulation of the herpes simplex virus (HSV). Biovex recently completed a Phase II clinical trial for the treatment of melanoma with its OncoVEX GM-CSF product. The results of this trial showed that the product was capable of inducing a lasting response in a large proportion of the patients treated. The company is currently carrying out Phase III trials for this indication.
January 2011: Amgen completed the acquisition of BioVex for total consideration of up to $1 billion should it reach its milestones. 

 

Latest news
Sector 
SaaS / Cloud
Entry Date 
2009
Exit Date 
2010
Buyer 
Cloudmark
Business 
Venture Capital

Bizanga

Specialist in email management

Bizanga, a specialist in email management, sold its IMP (Intelligent Message Processor) email traffic management platform to US partner Cloudmark. Bizanga retains its storage business and has changed its name to Bizanga Store.

Latest news
Sector 
Pharma
Entry Date 
2006
Exit Date 
2009
Buyer 
Acquisition of a Pangenetics asset by Abbott
Business 
Venture Capital

PanGenetics

Development of innovative and unique humanised therapeutic antibodies.

Dutch company specialised in the clinical development of therapeutic antibodies. The company sold exclusive rights to its PG-110 antibody to Abbott for $190 million. Developed by PanGenetics, PG-110 is a humanised antibody targeting nerve growth factor (in phase I clinical trials). To date, the company has raised close to €51 million in the three funding rounds completed between 2005 and 2008. The deal is an endorsement of the company’s novel strategy predicated on the development of proprietary products and the licensing of new products, excluding R&D activities.

Sector 
Pharma
Entry Date 
2005
Exit Date 
2009
Buyer 
Sanofi Aventis
Business 
Venture Capital

Fovea Pharmaceuticals

Ocular franchise dedicated to discovering therapies for retinal conditions

Founded in 2005 to break new ground in the treatment of retinal conditions, Fovea Pharmaceuticals has built an R&D portfolio covering ocular conditions with unmet needs, and now forms Sanofi’s Ophthalmology division. Its core approach is to put patients at the heart of its strategy, thanks to its presence at the Institut de la Vision located on the Quinze-Vingts hospital campus. Its team consists almost exclusively of research scientists. 
The company was bought by Sanofi Aventis in 2009 in a deal worth up to €370 million.

 

Sector 
Pharma
Entry Date 
2004
Exit Date 
2009
Buyer 
Pharma Omnium International
Business 
Venture Capital

Mutabilis

Discovery of new therapeutic targets for the development of anti-infectives

Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.

Sector 
Pharma
Entry Date 
2002
Exit Date 
2007
Buyer 
Biolipox merged with Orexo in November 2007
Business 
Venture Capital

Orexo

Specialty pharmaceutical company developing drugs from a proprietary delivery platform

Orexo is a Swedish pharmaceutical company specialised in the development of new patented drugs by combining well-known molecules with innovative technologies, chiefly for the treatment of inflammatory and respiratory conditions. Orexo possesses a large portfolio of products at an advanced development stage and which have already demonstrated therapeutic benefits. In 2007, Orexo merged with Biolipox, a pharmaceutical research & development company focused on inflammatory conditions, through an increase in capital valuing the company at an aggregate amount of $137 million. Orexo (ORX) is listed on the Stockholm Stock Exchange.
(N/a: Initial investment: Omnes Capital purchased a stake in Biolipox in December 2002)

Sector 
Web
Entry Date 
2002
Exit Date 
2007
Buyer 
IPO
Business 
Venture Capital

Adenclassifieds

Online classified advertising

Online classified advertising (jobs, training and properties).

Sector 
Web
Entry Date 
2006
Exit Date 
2007
Buyer 
Neuf Telecom
Business 
Venture Capital

Erenis

Fibre optics and ISP

Fibre-optic connections and internet service provider for consumers.

Sector 
Hardware
Entry Date 
2001
Exit Date 
2006
Buyer 
PdfSolutions
Business 
Venture Capital

SI automation

Enhance semiconductor manufacturing yields

Yield enhancement solutions for semiconductor manufacturers.

Pages

NewsRoom
Press release
25 September 2019
Newronika raises an €8.4 m series-A round
Newronika raises an €8.4 m series-A round
Press release
23 September 2019
Wizaplace raises 13 million euros to become leader in creating B2B marketplaces
Wizaplace raises 13 million euros to become leader in creating B2B marketplaces
Press release
19 September 2019
Omnes sells Eyssautier Group to insurance broker Verlingue

Omnes sells Eyssautier Group to insurance broker Verlingue
Publication
Scope, the Omnes review, November 2018
Press release
12 September 2019
InCA group consolidates its platform with the acquisition of Natur'Habitat & Natur'Habitat L'Atelier de Pose, completing its second buyout since Omnes became shareholder
InCA group consolidates its platform with the acquisition of Natur'Habitat & Natur'Habitat L'Atelier de Pose, completing its second buyout since Omnes became shareholder
Press release
18 July 2019
Omnes invests in Belgian consultancy firm Intys and signs Omnes Croissance 4 fund’s first international deal



Omnes invests in Belgian consultancy firm Intys and signs Omnes Croissance 4 fund’s first international deal
Press release
04 July 2019
Omniprom is established to operate real estate projects with high energy and environmental performance
Omniprom is established to operate real estate projects with high energy and environmental performance

Pages